Evidence mapPaperPMID 21121941Full record

ArticleClinical endocrinology2011

When should an insulin sensitizing agent be used in the treatment of polycystic ovary syndrome?

Stephen Franks

Registry-linked trialOpen access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Clinical endocrinology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02491333 (The Effect of Acupuncture on Insulin Sensitivity of Women With Polycystic Ovary Syndrome and Insulin Resistance), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
5.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02491333 phase3completedstarted 2015, after this paper: background citation

The Effect of Acupuncture on Insulin Sensitivity of Women With Polycystic Ovary Syndrome and Insulin Resistance: a Randomized Controlled Trial

Ran2015Enrolled342Registered outcomes12Posted comparisons0ConditionsInsulin Resistance, Polycystic Ovary SyndromeArmsMetformin, placebo metformin, sham acupuncture, true acupuncture
Open the trial in the graph
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 39 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Ovulation induction by metformin among obese versus non-obese women with polycystic ovary syndrome.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2017
    Article
  5. Article
  6. Polycystic ovary syndrome: current status and future perspective.Frontiers in bioscience (Elite edition) · 2014 · on this map
    Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Stephen FranksInstitute of Reproductive & Developmental Biology, Imperial College London, Hammersmith Hospital, London, UK. s.franks@imperial.ac.uk
Hammersmith Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Polycystic ovary syndrome (PCOS) is associated with insulin resistance and an increased risk of developing type 2 diabetes mellitus. The attendant hyperinsulinaemia is also thought to contribute to the mechanism of anovulation in PCOS. Both metabolic and reproductive abnormalities are amplified by obesity and the treatment of first choice for overweight or obese women with PCOS is modification of diet and lifestyle. Nevertheless, changes in diet and exercise are, for many subjects, not easy to sustain and there seems an obvious place for insulin sensitizing agents in management of both reproductive and metabolic disturbances. Of the available agents affecting insulin sensitivity, metformin has been the most widely used but despite an enormous literature reporting beneficial effects on reproductive, cutaneous and metabolic manifestations of PCOS, its efficacy is unproven apart from in those subjects with impaired glucose tolerance or frank diabetes. Metformin at least has an assured safety record whereas both efficacy and safety of other insulin sensitizing agents in women of reproductive age, such as thiazolidinediones and glucagon-like peptide analogues, remains to be established.

Indexed as

FemaleHumansHypoglycemic AgentsInsulinInsulin ResistanceMetforminPolycystic Ovary SyndromeHypoglycemic AgentsInsulinMetformin

Identifiers

PMID21121941
OpenAlexW1583824277

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.